Lantern Pharma Inc.: ARMISTICE CAPITAL, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital LLC disclosed a stake exceeding 5% in Lantern Pharma Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005243). The exact share count and percentage were not specified in the headline disclosure. The move signals active institutional interest in the clinical-stage oncology company. Investors will watch for further detail on the position's size and intent in subsequent filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Lantern Pharma Inc.